The Food and Drug Administration on Aug. 23 approved Cara Therapeutics’ drug to treat moderate-to-severe itching in patients with chronic kidney disease undergoing dialysis, making Korsuva the first therapy for the ailment in the United States.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-FDA-declines-to-approve-Avenues-non-opioid-painkiller-again-shares-drop-Reuters-6-14-21.jpg503960Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-08-23 22:07:112021-08-24 02:50:06FDA approves Cara’s drug for severe itching in kidney disease patients